3 Great Reasons to Buy Guardant Health
Chances are, you know someone whose life has been affected by cancer, a disease that will kill more than 600,000 people in the United States this year. Guardant Health (NASDAQ: GH) is fighting back.
The medical diagnostics company markets liquid biopsies (blood tests) that help treat advanced-stage cancer patients by identifying their tumors through the use of genetic testing. Guardant is also developing blood tests that could provide early cancer detection.
The company's blood tests are a much less intrusive method than traditional tissue biopsies that can require surgical procedures and costly hospital stays. After the cancerous cells or DNA fragments found in the blood are genetically analyzed, Guardant provides recommendations to oncologists who want to find the most specialized treatment possible for their patients. The company's work can make a difference for families facing the devastating effects of the disease.
Source Fool.com
